Last updated: March 21, 2026
What is NDC 16714-0996?
NDC 16714-0996 is a drug listed in the National Drug Code Directory. Based on available data, it is identified as Eliquis (apixaban) 2.5 mg tablets, indicated for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, along with other approved indications.
Market Overview
Eliquis (apixaban) has become a leading anticoagulant medication, competing primarily against Xarelto (rivaroxaban) and Pradaxa (dabigatran). The following outlines its market position, revenue, and growth potential.
Current Market Size
- Global anticoagulants market (2022): Estimated at $12.2 billion and projected to grow at a CAGR of 7.2% through 2027[1].
- U.S. market share (2022): Eliquis holds roughly 40% of the anticoagulant market, with annual sales surpassing $7 billion[2].
Historical Revenue Data
| Year |
U.S. Sales (Billion USD) |
Market Share (%) |
Key Competitors |
| 2020 |
5.4 |
37 |
Xarelto, Pradaxa |
| 2021 |
6.1 |
39 |
Xarelto, Pradaxa |
| 2022 |
7.2 |
40 |
Xarelto, Pradaxa |
Market Drivers
- Aging population increases atrial fibrillation prevalence.
- Expanding indications, including deep vein thrombosis (DVT) and pulmonary embolism (PE) prevention.
- Favorable safety profile relative to warfarin.
Market Challenges
- Pricing pressures due to biosimilar/equivalent competition.
- Reimbursement limitations in certain payer segments.
- Patent expiration and generic entry pressures expected post-2025.
Price Analysis
Current Pricing
In 2023, average wholesale acquisition cost (AWAC) for Eliquis 2.5 mg tablets is approximately $20 per tablet[3].
| Price Parameter |
Value |
| Average Wholesale Price (AWP) |
$20 per tablet |
| Typical course (60 tablets for a 30-day supply) |
$1,200 per month |
Insurance and Reimbursement
The out-of-pocket cost for insured patients varies. Commercial insurers often have negotiated discounts, reducing patient copays.
- Average copay with commercial insurance: $10–$15 per prescription.
- Medicaid/Medicare Part D: Significant discounts negotiated, often bringing patient costs below $5.
Comparison to Competitors
| Drug |
Dose |
Typical Monthly Cost |
Notes |
| Eliquis |
2.5 mg twice daily |
$1,200 |
Premium pricing |
| Xarelto |
2.5 mg once daily |
$1,000–$1,200 |
Similar market segment |
| Pradaxa |
110 mg twice daily |
$800–$1,000 |
Slightly lower cost |
Future Price Projections
Patent and Market Dynamics
- Eliquis patent protection is expected to expire globally in 2025–2026[4].
- Potential entry of biosimilars or licensed generics could reduce price points.
Price Trends (2023–2027)
| Year |
Estimated Price per Tablet |
Expected Market Impact |
| 2023 |
$20 |
Stable, high premium |
| 2024 |
$18–$20 |
Slight decline with patent expiry approaching |
| 2025 |
$15–$18 |
Steady decline anticipated due to biosimilar competition |
| 2026 |
$10–$15 |
Significant drop expected post-patent expiration |
Factors Influencing Prices
- Patent expiration: Drives generic entry and price competition.
- Insurance negotiations: Payors leverage competition to negotiate discounts.
- Manufacturing costs: Likely to decrease with patent expiry and scale efficiencies.
- Regulatory approvals: Incremental approvals for biosimilars can precipitate price reductions.
Key Market Risks and Opportunities
Risks
- Patent challenges or legal delays could postpone generic entry.
- Market saturation leading to pricing pressure.
- Increased competition from biosimilars and newer anticoagulants.
Opportunities
- Expansion into new indications (e.g., venous thromboembolism prevention).
- Growing elderly population increasing demand.
- Strategic licensing or partnership agreements for biosimilar development.
Key Takeaways
- NDC 16714-0996 (Eliquis 2.5 mg) is among the premium anticoagulants in the U.S., with annual sales surpassing $7 billion.
- Market growth is driven by expanding indications and demographic shifts but faces pricing scrutiny and patent expiration risks.
- Current pricing is approximately $20 per tablet in wholesale terms, with substantial discounts for insured patients.
- Price projections indicate a decline to $10–$15 per tablet by 2026, primarily driven by patent expiration and biosimilar competition.
- Market share remains strong, but future profitability depends on successful navigation of patent and competition dynamics.
FAQs
Q1: When is Eliquis patent expiration expected?
Patent protections expire in the U.S. in 2025, with some jurisdictions experiencing different timelines.
Q2: What are the main competitors of Eliquis?
Xarelto and Pradaxa are the primary competitors; generics are anticipated post-2025.
Q3: How does pricing vary across insurance providers?
Insurance negotiations typically result in negotiated discounts, reducing patient out-of-pocket costs significantly.
Q4: What are the key indications for Eliquis?
Prevention of stroke and systemic embolism in non-valvular atrial fibrillation, and treatment/prevention of DVT and PE.
Q5: What impact will biosimilar entry have on Eliquis?
Biosimilars are expected to reduce prices significantly after patent expiry, potentially halving or more the current costs.
References
- MarketWatch. (2022). Global anticoagulants market size and growth. Retrieved from https://www.marketwatch.com
- IQVIA. (2023). U.S. pharmaceutical sales data.
- Redbook. (2023). Average wholesale prices for Eliquis.
- FDA. (2022). Patent status of Eliquis (apixaban).
